|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
OPIOD ANALGESICS IN HIGH DOSE MAY RESULT IN DROP IN HEART RATE AND CARDIAC OUTPUT
|
OPIATES DELAY ABSORPTION DUE TO SLOW GASTRIC EMPTYING
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
MAOI ON CONCURRENT ADMINISTRATION MAY CAUSE MARKED HYPERPYREXIA, CONVULSION & COMA. HENCE SHOULD NOT BE USED WITHIN 2 WEEKS OF STOPPING MAOIS
|
CLARITHROMYCIN INCREASES PLASMA CONCENTRATION BY 30% AND MEAN HALF LIFE FROM 1.2 TO 1.6 HRS
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
MICONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
METOCLOPRAMIDE EFFECTS ON G.I. MOTILITY ARE ANTAGONISED BY THE DRUG
|
PANTAZOCINE MAY CAUSE INCREASED RISK OF RESPIRATORY DEPRESSION & HYPOTENSION
|
ADDITIVE CNS DEPRESSANT EFFECTS
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
DIAZEPAM MAY CAUSE RESPIRATORY AND CARDIAC COLLAPSE
|
FLUOXETINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF POSTOPERATIVE RESPIRATORY DEPRESSION OR ENHANCE IT
|
CO-ADMINISTRATION CAN LEAD TO REDUCED EFFECTS OF PEGVISOMANT, SO HIGHER DOSES ARE NEEDED TO ACHIEVE RESULTS
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
MAY INCREASE DROWSINESS EFFECT
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
ORTHOSTATIC HYPOTENSION IS AGGRAVATED
|
ERYTHROMYCIN INCREASES PLASMA CONCENTRATION OF THE DRUG DUE TO REDUCED CLEARANCE
|
ERYTHROMYCIN INCREASES PLASMA CONCENTRATION OF THE DRUG DUE TO REDUCED CLEARANCE
|
ERYTHROMYCIN INCREASES PLASMA CONCENTRATION OF THE DRUG DUE TO REDUCED CLEARANCE
|
ERYTHROMYCIN INCREASES PLASMA CONCENTRATION OF THE DRUG DUE TO REDUCED CLEARANCE
|
KETAMINE EFFECT IS PROLONGED WITH SUBSEQUENT DELAY IN RECOVERY DUE TO CONCOMITANT USE
|
CO-ADMINISTRATION WITH A PURE AGONIST OPIOID ANAGESIC LIKE LEVORPHANOL IS NOT RECOMMENDED
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
FLUCONAZOLE INCREASES SERUM PLASMA CONCENTRATION OF THE DRUG
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|